These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 23573743

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema: summary of primary findings and conclusions.
    O'Malley PG.
    Arch Intern Med; 2012 Jul 09; 172(13):1014-5. PubMed ID: 22688778
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Managed care opportunities and approaches to supporting appropriate selection of treatment for sight preservation.
    Cannon E.
    Am J Manag Care; 2019 Jul 09; 25(10 Suppl):S182-S187. PubMed ID: 31419089
    [Abstract] [Full Text] [Related]

  • 10. Response to Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us?
    O'Shea JG.
    Clin Exp Optom; 2012 Sep 09; 95(5):541-3. PubMed ID: 22672003
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A licence to cure.
    Aronson JK, Ferner RE.
    BMJ; 2015 Apr 01; 350():h1723. PubMed ID: 25834026
    [No Abstract] [Full Text] [Related]

  • 13. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.
    Hawkes N.
    BMJ; 2012 May 09; 344():e3275. PubMed ID: 22573655
    [No Abstract] [Full Text] [Related]

  • 14. Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?
    Harvey KJ, Day RO, Campbell WG, Lipworth W.
    Med J Aust; 2011 Jun 06; 194(11):567-8. PubMed ID: 21644867
    [Abstract] [Full Text] [Related]

  • 15. Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration.
    Johnson D, Sharma S.
    Curr Opin Ophthalmol; 2013 May 06; 24(3):205-12. PubMed ID: 23518613
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The results of switching between 2 anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age-related macular degeneration.
    Aslankurt M, Aslan L, Aksoy A, Erden B, Cekiç O.
    Eur J Ophthalmol; 2013 May 06; 23(4):553-7. PubMed ID: 23516253
    [Abstract] [Full Text] [Related]

  • 18. Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration.
    Shaikh AH, Toussaint BW, Miller DM, Petersen MR, Foster RE, Riemann CD, Hutchins RK, Sisk RA.
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jan 06; 46(1):62-6. PubMed ID: 25559511
    [Abstract] [Full Text] [Related]

  • 19. Bevacizumab in ophthalmology: the controversy moves forward.
    Gillies MC.
    Clin Exp Ophthalmol; 2010 May 06; 38(4):333-4. PubMed ID: 20642588
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.